Chronic kidney disease-mineral and bone disorders (CKD-MBDs): What the endocrinologist needs to know

Farhad Zangeneh, Bart Clarke, Daniel Hurley, Nelson Watts, Paul Miller

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: Chronic kidney disease-mineral and bone disorders (CKD-MBDs) are a spectrum of abnormalities involving skeletal hormones, minerals, and bone turnover and mineralization. This paper focuses on what the endocrinologist should know about the assessment and management of skeletal and metabolic disorders in CKD-MBDs.Methods: Relevant literature was reviewed to (1) define disturbances of minerals and hormones in the course of CKD; (2) identify the variable radiographic and histomorphometric changes of CKD-MBDs; (3) review the association among CKD-MBDs, vascular calcification, cardiovascular disease (CVD), and mortality; and (4) clarify issues in CKD-MBDs therapy.Results: Assessment and treatment of CKD-MBDs is complicated by progressive changes in bone minerals and skeletal regulatory hormones as kidney function declines. CKD-MBDs are associated with fracture risk, and studies demonstrate that bone mineral density can be used to assess bone loss and fracture risk in these patients. Treatment of CKD-MBDs continues to evolve. Use of calcium, phosphate binders, vitamin D, vitamin D-receptor analogs, and drugs for osteoporosis and CKD-MBDs treatment are discussed in the context of safety and efficacy for patients with CKD.Conclusion: The association of CKD with bone disease, vascular calcification, CVD, and mortality mandates earlier recognition and treatment of CKD-MBDs. Osteoporosis as a distinct entity can be diagnosed and managed in CKD, although assessment of osteoporosis becomes challenging in late (stage 4 to 5) CKD. Diabetes is common in early (stage 1 to 3) CKD. In addition, 96% of all individuals identified as having CKD have early CKD. The endocrinologist is uniquely positioned to address and treat both diabetes and many of the metabolic and skeletal disorders associated with early CKD-MBDs, including osteoporosis.

Original languageEnglish (US)
Pages (from-to)500-516
Number of pages17
JournalEndocrine Practice
Volume20
Issue number5
DOIs
StatePublished - May 1 2014

Fingerprint

Chronic Kidney Disease-Mineral and Bone Disorder
Osteoporosis
Minerals
Vascular Calcification
Hormones
Endocrinologists
Cardiovascular Diseases
Therapeutics
Physiologic Calcification
Calcitriol Receptors
Mortality
Bone Remodeling
Bone Diseases
Bone Fractures
Patient Safety
Vitamin D
Bone Density

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Chronic kidney disease-mineral and bone disorders (CKD-MBDs) : What the endocrinologist needs to know. / Zangeneh, Farhad; Clarke, Bart; Hurley, Daniel; Watts, Nelson; Miller, Paul.

In: Endocrine Practice, Vol. 20, No. 5, 01.05.2014, p. 500-516.

Research output: Contribution to journalArticle

Zangeneh, Farhad ; Clarke, Bart ; Hurley, Daniel ; Watts, Nelson ; Miller, Paul. / Chronic kidney disease-mineral and bone disorders (CKD-MBDs) : What the endocrinologist needs to know. In: Endocrine Practice. 2014 ; Vol. 20, No. 5. pp. 500-516.
@article{c39b921552824de79e62a2ceee2aae0c,
title = "Chronic kidney disease-mineral and bone disorders (CKD-MBDs): What the endocrinologist needs to know",
abstract = "Objective: Chronic kidney disease-mineral and bone disorders (CKD-MBDs) are a spectrum of abnormalities involving skeletal hormones, minerals, and bone turnover and mineralization. This paper focuses on what the endocrinologist should know about the assessment and management of skeletal and metabolic disorders in CKD-MBDs.Methods: Relevant literature was reviewed to (1) define disturbances of minerals and hormones in the course of CKD; (2) identify the variable radiographic and histomorphometric changes of CKD-MBDs; (3) review the association among CKD-MBDs, vascular calcification, cardiovascular disease (CVD), and mortality; and (4) clarify issues in CKD-MBDs therapy.Results: Assessment and treatment of CKD-MBDs is complicated by progressive changes in bone minerals and skeletal regulatory hormones as kidney function declines. CKD-MBDs are associated with fracture risk, and studies demonstrate that bone mineral density can be used to assess bone loss and fracture risk in these patients. Treatment of CKD-MBDs continues to evolve. Use of calcium, phosphate binders, vitamin D, vitamin D-receptor analogs, and drugs for osteoporosis and CKD-MBDs treatment are discussed in the context of safety and efficacy for patients with CKD.Conclusion: The association of CKD with bone disease, vascular calcification, CVD, and mortality mandates earlier recognition and treatment of CKD-MBDs. Osteoporosis as a distinct entity can be diagnosed and managed in CKD, although assessment of osteoporosis becomes challenging in late (stage 4 to 5) CKD. Diabetes is common in early (stage 1 to 3) CKD. In addition, 96{\%} of all individuals identified as having CKD have early CKD. The endocrinologist is uniquely positioned to address and treat both diabetes and many of the metabolic and skeletal disorders associated with early CKD-MBDs, including osteoporosis.",
author = "Farhad Zangeneh and Bart Clarke and Daniel Hurley and Nelson Watts and Paul Miller",
year = "2014",
month = "5",
day = "1",
doi = "10.4158/EP12291.RA",
language = "English (US)",
volume = "20",
pages = "500--516",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "5",

}

TY - JOUR

T1 - Chronic kidney disease-mineral and bone disorders (CKD-MBDs)

T2 - What the endocrinologist needs to know

AU - Zangeneh, Farhad

AU - Clarke, Bart

AU - Hurley, Daniel

AU - Watts, Nelson

AU - Miller, Paul

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Objective: Chronic kidney disease-mineral and bone disorders (CKD-MBDs) are a spectrum of abnormalities involving skeletal hormones, minerals, and bone turnover and mineralization. This paper focuses on what the endocrinologist should know about the assessment and management of skeletal and metabolic disorders in CKD-MBDs.Methods: Relevant literature was reviewed to (1) define disturbances of minerals and hormones in the course of CKD; (2) identify the variable radiographic and histomorphometric changes of CKD-MBDs; (3) review the association among CKD-MBDs, vascular calcification, cardiovascular disease (CVD), and mortality; and (4) clarify issues in CKD-MBDs therapy.Results: Assessment and treatment of CKD-MBDs is complicated by progressive changes in bone minerals and skeletal regulatory hormones as kidney function declines. CKD-MBDs are associated with fracture risk, and studies demonstrate that bone mineral density can be used to assess bone loss and fracture risk in these patients. Treatment of CKD-MBDs continues to evolve. Use of calcium, phosphate binders, vitamin D, vitamin D-receptor analogs, and drugs for osteoporosis and CKD-MBDs treatment are discussed in the context of safety and efficacy for patients with CKD.Conclusion: The association of CKD with bone disease, vascular calcification, CVD, and mortality mandates earlier recognition and treatment of CKD-MBDs. Osteoporosis as a distinct entity can be diagnosed and managed in CKD, although assessment of osteoporosis becomes challenging in late (stage 4 to 5) CKD. Diabetes is common in early (stage 1 to 3) CKD. In addition, 96% of all individuals identified as having CKD have early CKD. The endocrinologist is uniquely positioned to address and treat both diabetes and many of the metabolic and skeletal disorders associated with early CKD-MBDs, including osteoporosis.

AB - Objective: Chronic kidney disease-mineral and bone disorders (CKD-MBDs) are a spectrum of abnormalities involving skeletal hormones, minerals, and bone turnover and mineralization. This paper focuses on what the endocrinologist should know about the assessment and management of skeletal and metabolic disorders in CKD-MBDs.Methods: Relevant literature was reviewed to (1) define disturbances of minerals and hormones in the course of CKD; (2) identify the variable radiographic and histomorphometric changes of CKD-MBDs; (3) review the association among CKD-MBDs, vascular calcification, cardiovascular disease (CVD), and mortality; and (4) clarify issues in CKD-MBDs therapy.Results: Assessment and treatment of CKD-MBDs is complicated by progressive changes in bone minerals and skeletal regulatory hormones as kidney function declines. CKD-MBDs are associated with fracture risk, and studies demonstrate that bone mineral density can be used to assess bone loss and fracture risk in these patients. Treatment of CKD-MBDs continues to evolve. Use of calcium, phosphate binders, vitamin D, vitamin D-receptor analogs, and drugs for osteoporosis and CKD-MBDs treatment are discussed in the context of safety and efficacy for patients with CKD.Conclusion: The association of CKD with bone disease, vascular calcification, CVD, and mortality mandates earlier recognition and treatment of CKD-MBDs. Osteoporosis as a distinct entity can be diagnosed and managed in CKD, although assessment of osteoporosis becomes challenging in late (stage 4 to 5) CKD. Diabetes is common in early (stage 1 to 3) CKD. In addition, 96% of all individuals identified as having CKD have early CKD. The endocrinologist is uniquely positioned to address and treat both diabetes and many of the metabolic and skeletal disorders associated with early CKD-MBDs, including osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=84900442416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900442416&partnerID=8YFLogxK

U2 - 10.4158/EP12291.RA

DO - 10.4158/EP12291.RA

M3 - Article

C2 - 24325991

AN - SCOPUS:84900442416

VL - 20

SP - 500

EP - 516

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 5

ER -